General

People With Emotional Intelligence Less Likely To Be Susceptible To Fake News

Author : NewsGram Desk

People with high levels of emotional intelligence are less likely to be susceptible to 'fake news, a new study suggests. The studies, published in the journal PLOS ONE, indicate that those who identified the types of news correctly were most likely to score highly in the EQ tests.

"Fake news on social media is now a matter of considerable public and governmental concern," said researcher Tony Anderson from the University of Strathclyde in the UK. "Research on dealing with this issue is still in its infancy but recent studies have started to focus on the psychological factors which might make some individuals less susceptible to fake news," Anderson added.

Follow NewsGram on Facebook to stay updated.

For the study, the research team invited nearly 100 participants to read a series of news items on social media and to ascertain whether they were real or fictitious, briefly describing the reasons for their answers.

They were also asked to complete a test to determine their levels of emotional intelligence (EQ or emotional quotient) and were asked a number of questions when considering the veracity of each news item.

Participants were presented with real and fabricated news stories on issues including health, crime, wealth inequality, and the environment. Fictitious items featured aspects including emotive language, brief information, and a lack of attributed sources. (IANS/SP)

Subscribe to our channels on YouTube and WhatsApp 

“One Month to Learn Hindi”: Delhi BJP Councillor Threatens Foreign Football Coach in Language Row

No Deaths Linked to Codeine Cough Syrup in Uttar Pradesh, Says CM Yogi

Obesity a Serious Public Health Challenge, Not a Cosmetic Issue: Union Minister Jitendra Singh

Indian Names Surface in Epstein Documents: PM Modi, Union Minister Hardeep Singh Puri and Anil Ambani Mentioned, What Does This Connection Suggest?

IIT Madras’ New Precision Nanoinjection Platform to Boost Breast Cancer Drug Delivery